Categories: News

Delivra Health Brands to Hold Conference Call to Discuss Results for the Year Ending June 30, 2024

Vancouver, British Columbia–(Newsfile Corp. – October 2, 2024) – Delivra Health Brands Inc. (TSXV: DHB) (OTCQB: DHBUF) (“Delivra Health” or the “Company“), a consumer packaged goods leader uniquely positioned in the health and wellness sector, is pleased to announce it will report its annual financial results for the year ending June 30, 2024, on Tuesday, October 8, 2024.

Conference Call Details

The Company will host a conference call on Tuesday, October 8, 2024, at 11:00 a.m. (EST) / 8:00 a.m. (PST) to discuss the financial results for the year ending June 30, 2024. Gord Davey, President and Chief Executive Officer, and Jack Tasse, Chief Financial Officer of the Company will be conducting a question-and-answer session following management’s prepared remarks.

Participant Dial-In Numbers:

All interested parties can join the conference call by dialing: 1-844-763-8274 (Canada/USA Toll Free) or +1-647-484-8814 (International Toll). Please dial in 10 minutes prior to the scheduled start time and ask to join the Delivra Health Brands call. A replay of the call will be available on the Company’s investor page by the end of the business day on Tuesday, October 8, 2024.

About Delivra Health Brands Inc.

Helping people take control of their health with alternative wellness solutions is what energizes the Delivra Health team! The Delivra Health portfolio features innovative brands like Dream Water® and LivRelief™, which deliver relief from common everyday issues like chronic pain, anxiety, and sleeplessness. Delivra Health products have allowed millions of customers to reclaim their mobility, energy, and in turn, quality of life. The websites of the Company’s two subsidiaries are  Dream Water® and  LivReliefTM. For more information, please visit  www.delivrahealthbrands.com.

Cautionary Note Regarding Forward-Looking Statements

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements include, among other things, statements with respect to the timing of reporting the Company’s annual financial results for the year ending June 30, 2024, and the timing of the conference call.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the cannabis markets where the Company operates; changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; employee relations and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution, and sale of cannabis and cannabis-related products in the markets where the Company operates. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Additional information regarding this and other risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s annual information form dated March 2, 2021, and under the heading “Risks and Uncertainties” in the Company’s management’s discussion and analysis dated May 15, 2024, for the three and nine months ended March 31, 2024, filed under the Company’s profile on SEDAR+ at www.sedarplus.ca.

Neither TSX Venture Exchange or its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.

Investor Relations:
Jack Tasse
Chief Financial Officer
IR@delivrahealth.com
1-877-915-7934

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/225399

Staff

Recent Posts

MedMira Announces the appointment of Vice President of Commercial Operations

MedMira Inc. continues its North-American expansion plan HALIFAX, NS / ACCESSWIRE / October 3, 2024…

22 mins ago

Charles Dadswell to step down as General Counsel, Illumina initiates search for successor

SAN DIEGO, Oct. 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in…

3 hours ago

OrthAlign Receives FDA 510(k) Clearance for Lantern® Hip

IRVINE, Calif., Oct. 3, 2024 /PRNewswire/ -- OrthAlign, Inc., a privately held medical device company,…

3 hours ago

Poseida Therapeutics Named to Newsweek’s List of the Top 200 America’s Most Loved Workplaces for 2024

Inclusion on list recognizes Poseida for employee sentiment and satisfaction SAN DIEGO, Oct. 3, 2024 /PRNewswire/…

3 hours ago

Westat Awarded AI Coordinating Center to Support NHLBI’s Precision Medicine Research

NHLBI recognizes Westat's expertise in artificial intelligence (AI) and machine learning (ML), in-depth knowledge of…

3 hours ago

NIPTE Announces The Industrial Workforce Development Consortium – A Pathway for Upskilling Employees in the Pharmaceutical Industry

An industrial consortium for workforce development has been established by NIPTE to develop a workforce…

3 hours ago